TLC502 is a novel nucleic acid drug developed by TLC BioSciences, utilizing RNA interference (RNAi) mechanisms combined with lipid nanoparticle (LNP) technology to target genes associated with osteoarthritis. It is engineered to reduce the degradation of collagen and aggrecan, key components of cartilage, functioning as a sustained protease inhibitor. This innovative approach aims to preserve joint integrity and slow the progression of osteoarthritis, offering a new hope for patients seeking to maintain joint health and mobility.
Please select the unit you wish to search and enter the keyword in the text field below.